CNS & Neurological Disorders - Drug Targets
Title:Meet Our Editorial Board Member
Volume: 15 Issue: 2
Author(s): Eric Murillo-Rodríguez
Affiliation:
Export Options
About this article
Cite this article as:
Murillo-Rodríguez Eric, Meet Our Editorial Board Member, CNS & Neurological Disorders - Drug Targets 2016; 15 (2) . https://dx.doi.org/10.2174/187152731502160215130930
DOI https://dx.doi.org/10.2174/187152731502160215130930 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Orphanin FQ / Nociceptin Receptor as a Novel Drug Target in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Lack of Regulatory Changes of µ-Opioid Receptors by 14-Methoxymetopon Treatment in Rat Brain. Further Evidence for Functional Selectivity
Current Pharmaceutical Design Glaucoma Disease: A Survey
Current Medical Imaging Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry 4-(1-Adamantyl)phenylalkylamines with Potential Antiproliferative Activity
Letters in Organic Chemistry Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Smoking Cessation in Schizophrenia
Current Psychiatry Reviews Adenosine Analogues as Opposite Modulators of the Cisplatin Resistance of Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends
Current Drug Safety The Relation between Stylometry and Neuroscience
Neuroscience and Biomedical Engineering (Discontinued) Immunotherapy for Malignant Melanoma Robert
Current Stem Cell Research & Therapy Diagnostics, Prognostic and Therapeutic Exploitation of Telomeres and Telomerase in Leukemias
Current Pharmaceutical Biotechnology Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease
Current Alzheimer Research Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer
Current Alzheimer Research Molecule of the Month
Current Topics in Medicinal Chemistry Supercritical Fluid Particle Design for Poorly Water-soluble Drugs (Review)
Current Pharmaceutical Design Anticonvulsant Effect of the Essential Oil and Methanolic Extracts of <i>Zataria multiflora</i> Boiss
Central Nervous System Agents in Medicinal Chemistry A traditional Chinese Medicine, YXQN, Reduces Amyloid-induced Cytotoxicity by Inhibiting Aβ42 Aggregation and Fibril Formation
Current Pharmaceutical Design Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets